1. Home
  2. EVAX

as of 03-17-2026 3:59pm EST

$3.78
$0.05
-1.31%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Founded: 2008 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 27.4M IPO Year: 2020
Target Price: $11.67 AVG Volume (30 days): 29.9K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.20 - $12.15 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -83.06% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Latest Evaxion Biotech News

EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing

All EVAX News

Share on Social Networks: